Business Wire

THALES

7.6.2022 09:02:10 CEST | Business Wire | Press release

Share
Cloud Data Breaches and Cloud Complexity on the Rise, Reveals Thales

The 2022 Thales Cloud Security Report , conducted by 451 Research, part of S&P Global Market Intelligence, reports that 45% of businesses have experienced a cloud-based data breach or failed audit in the past 12 months, up 5% from the previous year1 , raising even greater concerns regarding to protecting sensitive data from cybercriminals.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607005059/en/

Globally, cloud adoption and notably multicloud adoption, remains on the rise. In 2021, organisations worldwide were using an average amount of 110 software as a service (SaaS) applications2 , compared with just eight in 2015, showcasing a startlingly rapid increase. There has been a notable expansion in the use of multiple IaaS providers, with almost three-quarters (72%) of businesses using multiple IaaS providers, up from 57% the year before. The use of multiple providers has almost doubled in the last year, with one in five (20%) of respondents reporting using three or more providers.

Despite their increasing prevalence and use, businesses share common concerns about the increasing complexity of cloud services with the majority (51%) of IT professionals agreeing that it is more complex to manage privacy and data protection in the cloud. Additionally, the journey to the cloud is also becoming more complex, with the percentage of respondents reporting that they’re expecting to lift and shift, the simplest of migration tactics, dropping from 55% in 2021 to 24% currently.

Security Challenges of Multicloud Complexity

With increasing complexity comes an even greater need for robust cybersecurity. When asked what percentage of their sensitive data is stored in the cloud, a solid majority (66%) said between 21-60%. However, only a quarter (25%) said they could fully classify all data.

Additionally, nearly a third (32%) of respondents admitted to having to issue a breach notification to a government agency, customer, partner or employees. This should be a cause for concern among enterprises with sensitive data, particularly in highly regulated industries.

Cyber-attacks also present an ongoing risk to cloud applications and data. Respondents reported an increasing prevalence of attacks, with a quarter (26%) citing an increase in malware, 25% in ransomware and one-fifth (19%) reporting seeing an increase in phishing/ whaling.

Protecting Sensitive Data

When it comes to securing data in multicloud environments, IT professionals view encryption as a critical security control. The majority of respondents cited encryption (59%) and key management (52%) as the security technologies they currently use to protect sensitive data in the cloud.

However, when asked what percentage of their data in the cloud is encrypted, only one in ten (11%) of respondents said between 81-100% is encrypted. Additionally, key management platform sprawl may be an issue for enterprises. Only 10% of respondents use one to two platforms, 90% use three or more, and almost one in five (17%) admitted using eight or more platforms.

Encryption should be a priority area for enterprises to focus on when it comes to securing data in the cloud. In fact, 40% of respondents stated that they were able to avoid the breach notification process because the stolen or leaked data was encrypted or tokenised, showcasing the tangible value of encryption platforms.

Additionally, it is encouraging to see signs enterprises embrace Zero Trust and investing accordingly. Nearly a third of respondents (29%) said they are already executing a Zero Trust strategy, a quarter (27%) said they are evaluating and planning one and, 23% said they are considering it. This is a positive result, but there is certainly still room to grow.

Sebastien Cano, Senior Vice President for Cloud Protection and Licensing activities at Thales said: “The complexity of managing multicloud environments cannot be overstated. Additionally, the growing importance of data sovereignty is increasingly raising questions for CISOs and Data Protection Officers when considering their cloud strategy, governance, and risk management. The challenge is not only where the sensitive data resides geographically, but even who has access to sensitive data inside the organisation.

There are various solutions such as encryption and key management. Last but not least, continuing to embrace a Zero Trust strategy will be essential in securing these complex environments, helping to ensure organisations can support their data and manage future challenges.”

Thales and 451 Research will discuss the findings in more detail during a webinar on 23 June 2022. To join, please visit the registration page .

About the 2022 Thales Global Cloud Security Study

As organizations step beyond the urgent actions of the last two years, they’re grappling with securing the more complex environments in which they now operate. The global edition of the 2022 Thales Cloud Security Study looked at various aspects of those impacts in a wide-ranging survey of security professionals and executive leadership that touched on issues including accelerated digital transformation, cloud migration, and the complexities of managing security in a multicloud world. The 2022 Thales Cloud Security Study is based on data from a survey of almost 2,800 security professionals and executive leaders. This research was conducted as an observational study and makes no causal claims.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.

Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.

PLEASE VISIT

Thales Group
Security


1 https://cpl.thalesgroup.com/cloud-security-research
2 https://www.statista.com/statistics/1233538/average-number-saas-apps-yearly/

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye